JP2015513535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513535A5 JP2015513535A5 JP2014558090A JP2014558090A JP2015513535A5 JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5 JP 2014558090 A JP2014558090 A JP 2014558090A JP 2014558090 A JP2014558090 A JP 2014558090A JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- phosphatidylserine
- use according
- receptor
- tim
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 26
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 7
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 7
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 7
- 108091005729 TAM receptors Proteins 0.000 claims 6
- 230000003993 interaction Effects 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 230000000840 anti-viral effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 241000710831 Flavivirus Species 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091006082 receptor inhibitors Proteins 0.000 claims 3
- 241000710929 Alphavirus Species 0.000 claims 2
- 102100032231 Caveolae-associated protein 2 Human genes 0.000 claims 2
- 108050005259 Caveolae-associated protein 2 Proteins 0.000 claims 2
- 101150022345 GAS6 gene Proteins 0.000 claims 2
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical group OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102100034283 Annexin A5 Human genes 0.000 claims 1
- 241001502567 Chikungunya virus Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims 1
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305193 | 2012-02-21 | ||
| EP12305193.0 | 2012-02-21 | ||
| EP12306281.2 | 2012-10-17 | ||
| EP12306281 | 2012-10-17 | ||
| PCT/EP2013/053391 WO2013124327A1 (en) | 2012-02-21 | 2013-02-20 | Tim receptors as virus entry cofactors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015513535A JP2015513535A (ja) | 2015-05-14 |
| JP2015513535A5 true JP2015513535A5 (cg-RX-API-DMAC7.html) | 2016-03-10 |
Family
ID=47739275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558090A Pending JP2015513535A (ja) | 2012-02-21 | 2013-02-20 | ウイルス侵入補助因子としてのｔｉｍレセプター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160017035A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2817327A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015513535A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014021068A8 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN07023A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014010016A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013124327A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015509943A (ja) | 2012-02-21 | 2015-04-02 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ウイルス侵入補助因子としてのｔａｍレセプター |
| US11116818B2 (en) * | 2012-12-13 | 2021-09-14 | Children's Medical Center Corporation Dana-Farber Cancer Institute | Compositions and methods for inhibiting viral entry |
| WO2015092035A1 (en) * | 2013-12-20 | 2015-06-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cd300a receptors as virus entry cofactors |
| EP3206709A1 (en) * | 2014-10-15 | 2017-08-23 | Annexin Pharmaceuticals AB | Therapeutic composition comprising annexin v |
| KR102632022B1 (ko) * | 2014-12-05 | 2024-01-31 | 후지필름 가부시키가이샤 | Tim 단백질 결합 담체, 당해 담체를 사용한 세포외막소포 및 바이러스의 취득 방법, 제거 방법, 검출 방법 그리고 당해 담체를 포함하는 키트 |
| CA3024508A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| US20210024582A1 (en) * | 2018-03-29 | 2021-01-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric tim-3 fusion protein |
| US11197910B1 (en) * | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
| CN119639892A (zh) * | 2024-11-13 | 2025-03-18 | 浙江大学 | 一种分子标志物tim1及其在卵巢透明细胞癌中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993023569A1 (en) | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| US6756054B1 (en) | 1996-05-24 | 2004-06-29 | Ic-Vec Limited | Polycationic sterol derivatives as transfection agents |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
| DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| DE69834038D1 (de) | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
| WO1999054459A2 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
| AU6815901A (en) | 2000-06-02 | 2001-12-17 | Zycos Inc | Delivery systems for bioactive agents |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| AU2002305094B2 (en) | 2001-03-26 | 2007-01-11 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| WO2002076427A2 (en) | 2001-03-26 | 2002-10-03 | Thomas Jefferson University | Ph sensitive liposomal drug delivery |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| US20030203865A1 (en) | 2001-04-30 | 2003-10-30 | Pierrot Harvie | Lipid-comprising drug delivery complexes and methods for their production |
| DE10127526A1 (de) | 2001-05-31 | 2002-12-12 | Novosom Ag | Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln |
| US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
| US20030157030A1 (en) | 2001-11-02 | 2003-08-21 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
| WO2003057190A1 (en) | 2001-12-31 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| US20060051315A1 (en) | 2002-02-01 | 2006-03-09 | Scaria Puthupparampil V | Polymers for delivering peptides and small molecules in vivo |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| EP1476492A1 (en) | 2002-02-22 | 2004-11-17 | Insert Therapeutics Inc. | Carbohydrate-modified polymers, compositions and uses related thereto |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| US20030198664A1 (en) | 2002-03-29 | 2003-10-23 | Sullivan Sean Michael | Lipid mediated screening of drug candidates for identification of active compounds |
| EP1507561B1 (en) | 2002-05-24 | 2009-07-15 | Mirus Bio Corporation | Compositions for delivering nucleic acids to cells |
| US7682626B2 (en) | 2003-02-07 | 2010-03-23 | Roche Madison Inc. | Polyvinylethers for delivery of polynucleotides to mammalian cells |
| EP2173342A2 (en) | 2007-06-22 | 2010-04-14 | ETH Zurich | Antivirals |
| US8415361B2 (en) * | 2007-11-09 | 2013-04-09 | The Salk Institute For Biological Studies | Use of TAM receptor inhibitors as antimicrobials |
| US9192649B2 (en) | 2008-10-17 | 2015-11-24 | London Health Sciences Centre Research Inc. | Annexin and its use to treat inflammatory disorders |
| CA2802344C (en) * | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| JP2015509943A (ja) | 2012-02-21 | 2015-04-02 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ウイルス侵入補助因子としてのｔａｍレセプター |
-
2013
- 2013-02-20 US US14/379,879 patent/US20160017035A1/en not_active Abandoned
- 2013-02-20 IN IN7023DEN2014 patent/IN2014DN07023A/en unknown
- 2013-02-20 WO PCT/EP2013/053391 patent/WO2013124327A1/en not_active Ceased
- 2013-02-20 JP JP2014558090A patent/JP2015513535A/ja active Pending
- 2013-02-20 MX MX2014010016A patent/MX2014010016A/es unknown
- 2013-02-20 BR BR112014021068A patent/BR112014021068A8/pt not_active IP Right Cessation
- 2013-02-20 EP EP13704966.4A patent/EP2817327A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015513535A5 (cg-RX-API-DMAC7.html) | ||
| WO2015042308A3 (en) | Rna-based hiv inhibitors | |
| JP2014519662A5 (cg-RX-API-DMAC7.html) | ||
| Barcellini et al. | Rituximab therapy for autoimmune haematological diseases | |
| JP2012126742A5 (cg-RX-API-DMAC7.html) | ||
| JP2013172734A5 (cg-RX-API-DMAC7.html) | ||
| JP2018530530A5 (cg-RX-API-DMAC7.html) | ||
| JP2015526391A5 (cg-RX-API-DMAC7.html) | ||
| BR112014032999A2 (pt) | optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos | |
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| JP2014513356A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0813237B8 (pt) | composto, método para preparar o composto, medicamento, e, uso do composto | |
| JP2015521593A5 (cg-RX-API-DMAC7.html) | ||
| JP2017070307A5 (cg-RX-API-DMAC7.html) | ||
| JP2015516989A5 (cg-RX-API-DMAC7.html) | ||
| JP2014501492A5 (cg-RX-API-DMAC7.html) | ||
| JP2011528896A5 (cg-RX-API-DMAC7.html) | ||
| JP2013539454A5 (cg-RX-API-DMAC7.html) | ||
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| WO2013006795A3 (en) | Antiviral compositions and methods of their use | |
| JP2011172579A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510132A5 (cg-RX-API-DMAC7.html) | ||
| BR112013002296A2 (pt) | composição farmacêutica e respectivo uso e método para tratar doença infecciosa | |
| JP2013503110A5 (cg-RX-API-DMAC7.html) | ||
| CL2011001977A1 (es) | Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades. |